24/7 Market News Snapshot 12 September, 2025 – Cocrystal Pharma, Inc. Common Stock (NASDAQ:COCP)

September 12, 2025

DENVER, Colo., 12 September, 2025 (www.247marketnews.com) – (NASDAQ:COCP) are discussed in this article.
Cocrystal Pharma, Inc. (COCP) has garnered significant attention in the financial markets, evidenced by a striking pre-market surge of 21.39%, propelling its stock price to approximately $1.748, a notable increase from the previous closing of $1.440. The company is witnessing a robust trading volume of 3.90 million shares, reflecting heightened investor interest and confidence in its promising developments. This bullish momentum comes at a pivotal time as Cocrystal advances its research in the biopharmaceutical sector.

Recently, the company’s President and co-CEO, Dr. Sam Lee, showcased the latest progress on its lead drug candidate, CDI-988, during the 9th International Calicivirus Conference. CDI-988 is identified as a groundbreaking pan-viral protease inhibitor, which could potentially serve as the first oral antiviral for the prevention and treatment of norovirus, a major contributor to viral gastroenteritis globally. Dr. Lee articulated the compelling advantages of CDI-988, including its novel mechanism of action and impressive broad-spectrum antiviral efficacy.

The completion of a Phase 1 study, along with the receipt of FDA Investigational New Drug (IND) clearance for subsequent research, marks crucial advancements in the clinical journey of CDI-988. Dr. Lee expressed pride in presenting their Phase 1 data to domain experts, noting CDI-988’s promising safety profile observed in human intestinal tissue, which is critical given that this area is where norovirus infection occurs.

Furthermore, the company is preparing to initiate a Phase 1b human challenge study, authorized by the FDA, to assess CDI-988 as a prophylactic and treatment option for norovirus, with studies anticipated to commence by year-end. Cocrystal Pharma’s commitment to leveraging its innovative structure-based drug discovery platform continues to drive progress in addressing significant unmet medical needs in infectious diseases. Investors and stakeholders are advised to stay tuned for ongoing updates that signal the company’s potential to transform the antiviral landscape.

Related news for (COCP)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.